Company
Haleon PLC
LON:HLN
Haleon PLC is a consumer healthcare company that was demerged from GlaxoSmithKline PLC and Pfizer in July 2022. It is focused on improving the health and wellness around the world, with brands including toothpastes, painkillers and vitamins.
78 stories
Haleon prices $2bn bond sale to refinance debt
Haleon has priced $2 billion of dollar bonds in three tranches to refinance notes due in 2027.
Archive
Fuller Treacy Comment of the Day - Haleon is feeling in rude health after the flu season, and more...
Comment of the Day24th April 2023Eoin TreacyApr 25Video commentary for April 24th 2023A link to today's video commentary is posted in the Subscriber's Area.Some of the topics discussed include: stocks ease, dollar and gold firm as dollar ea
Haleon profit margin may disappoint, says Barclays
But the bank's analysts reckon a solid top-line performance for the first quarter will be "another piece of evidence to convince long only investors of Haleon’s structural growth potential"
Haleon looks good on J&J read across, reckons Credit Suisse
Credit Suisse believes the appetite for Haleon shares has increased sufficiently for GSK/Pfizer to consider unloading their residual holding
Haleon hikes organic revenue guidance after sustained price increases
From today, former parents GSK and Pfizer can start to sell down their combined 45% stake
Haleon, US inflation the standouts for Thursday
Thursday might see sales of Haleon stock from Pfizer and GSK after their lock-up ends while US inflation for October will be revealed
Haleon third-quarter update is big date for Pfizer stock overhang
Analysts have said that a larger-than-expected selldown from former parents Pfizer and GSK is one of the big risks for the shares
Barclays analysts impressed by Haleon sales targets
The bank has a 347p share price target on the Sensodyne, Panadol and Centrum owner
Haleon impresses UBS but Barclays 'prefers to wait until Zantac visibility improves'
Haleon's rejection of GSK and Pfizer's request for indemnification impressed analysts at UBS, who said this should allow the focus to return to the spun-off consumer healthcare group's "compelling prospects"
Haleon impresses with results and rejection of indemnity requests from GSK and Pfizer
The consumer healthcare group had lost around a quarter of its value since listing in mid-July
Haleon says positive momentum continuing, albeit at slower rate
Full-year revenue and profit margin guidance was unchanged and the group also reiterated medium-term guidance
Haleon half-year results will reveal if its brands are resisting trading-down effect
After debuting at 330p in mid-July with a £30.5bn market cap, the shares hit a Zantac-inspired low just above 241p earlier this month
Is Haleon a buy? This leading US broker delivers its verdict
“[Haleon’s] premiere trading update delivered a good set of numbers but more importantly, a solid first building block as the new management team sets out to build a track record of delivering on their guidance,” said Jefferies in a note to
Haleon raises revenue guidance after bumper first half
The former GSK consumer health business listed in both London and New York last week and is valued at just under £30bn
Haleon offers 'the best of both worlds', says Citi
The analysts said the company has "a strategic optionality offering a floor to valuation"
As Haleon shares squeezed by investor scepticism could a new bid emerge?
Prior to the demerger Unilever made a £50bn takeover bid for the business, which is now trading at less than £30mln
Archive
FTSE 100 ends higher on day UK temperature heats up to 40C for the first time
At the close, the UK blue-chip index was 73.04 points, or 1.0% higher at 7,296.28, below the session peak of 7,308.99 but well above the early low of 7,174.40
Haleon makes market debut as GSK and Pfizer complete consumer health spin-off
The new business was formed from consumer healthcare assets owned by the UK drugs giant, Pfizer and Novartis
Welcoming Haleon the ‘new (big) kid on the block’ on Monday
It is anticipated to have an equity value north of £33bn, which will place safely it in the top quarter of the FTSE 100